Company Overview and News

 
PNB MetLife files draft papers for IPO

2018-07-28 thehindubusinessline
PNB Metlife India Insurance Co.( PNB MetLife) has filed a draft red herring prospectus (DRHP) with market regulator SEBI for an initial public offering (IPO).
504000 ELPROINTL

 
PNB MetLife files DRHP, looks to dilute up to 25% via proposed IPO

2018-07-27 moneycontrol
PNB MetLife Insurance has filed the draft red herring prospectus (DRHP) for its initial public offering (IPO) with the Securities and Exchange Board of India (SEBI).
504000 ELPROINTL PNJZY 532461 PNB

 
Elpro International to sell nearly 1.33 per cent stake in PNB MetLife

2018-05-08 thehindubusinessline
Elpro International has agreed to sell approximately 1.33 per cent shareholding in PNB MetLife India Insurance Company for a total consideration of ₹134.22 crore. The decision is subject to satisfaction of certain conditions, including approval from the Insurance Regulatory and Development Authority of India and the Competition Commission of India. Elpro International has been holding 12.75 per cent stake in PNB MetLife Insurance since 2003.
504000 ELPROINTL 512068 DECNGOLD

 
Cresta Fund sells 19.76 lakh shares of Elpro International

2018-03-28 moneycontrol
On March 27, 2018 Cresta Fund sold 19,76,851 shares of Elpro International at Rs 48 on the BSE.
504000 ELPROINTL

 
Elpro’s ₹100-crore rights issue opens

2018-03-27 thehindubusinessline
The rights issue of Elpro International will open on Wednesday and close on April 11. It plans to raise up to ₹100 crore through the rights issue by offering 3.11 crore shares at ₹32.10 a share. The entitlement ratio is nine equity shares for every 40 held by existing shareholders in the company as on February 9. Meanwhile, exchange disclosures reveal that its promoters have been increasing their stakes in the firm through creeping acquisitions in the last few days.
504000 ELPROINTL 532693 PUNJLLOYD

 
The top buzzing midcap stocks to trade on March 19

2018-03-20 moneycontrol
Here are some of the top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. Keep an eye on Cipla, Elpro International, Gujarat State Petroleum Corporation (GSPL) and Binani Industries.
504000 ELPROINTL GUJGAS BINANIIND 539336 500059

 
Elpro to sell 1.25% equity in MetLife for Rs 125 crore

2018-03-19 moneycontrol
Elpro International today said it will offload 1.25 percent of its equity stake in PNB MetLife insurance company, which may fetch it about Rs 125 crore.
504000 ELPROINTL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...